Moreover, four (IL7R, FLT3, C1QC, and HLA-DRB5) of the 19 genes were selected for subsequent analysis because they have not been recently reported to be correlated with clinical outcome of CM. This evidence concerns the gene HLA-DRB5 and cutaneous mastocytosis.